<p>雅培（NYSE:ABT - 獲取免費報告）股票在週四創下 52 周新高。該公司交易價格最高達到 132.85 美元，最後交易價格為 132.92 美元，成交量為 547305 股。該股票此前收盤價為 132.13 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>雅培將在 2025 年超越醫療保健股票</li>
</ul>
<p>ABT 一直是多份分析師報告的主題。巴克萊在 1 月 27 日的研究報告中重申了 “增持” 評級，並將雅培的目標價從 149.00 美元上調至 158.00 美元。富國銀行在 1 月 23 日的研究報告中將雅培的目標價從 133.00 美元上調至 136.00 美元，並給予該股票 “增持” 評級。StockNews.com 在 2 月 12 日的研究報告中將雅培的評級從 “強力買入” 下調至 “買入”。Evercore ISI 在 1 月 2 日的研究報告中將雅培的目標價上調至 136.00 美元，並給予該股票 “買入” 評級。最後，斯蒂費爾·尼古拉斯在 1 月 23 日的報告中將雅培的目標價從 130.00 美元上調至 135.00 美元，並給予公司 “買入” 評級。四位股票研究分析師對該股票給予持有評級，十四位給予買入評級，一位給予強力買入評級。根據 MarketBeat.com 的數據，雅培目前的平均評級為 “適度買入”，平均目標價為 133.06 美元。</p>
<p><strong>閲讀我們關於 ABT 的最新報告</strong></p>
<h2>雅培股票上漲 0.4%</h2>
<ul>
<li>這些是適合長期投資的頂級健康股票</li>
</ul>
<p>該公司的市值為 2301.9 億美元，市盈率為 17.35，PEG 比率為 2.43，貝塔值為 0.75。該公司的速動比率為 1.14，流動比率為 1.60，債務股本比率為 0.32。該業務的 50 日移動平均價格為 119.93 美元，200 日移動平均價格為 116.53 美元。</p>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 1 月 22 日發佈了季度財報。這家醫療產品製造商報告該季度每股收益（EPS）為 1.34 美元，符合分析師的共識預期 1.34 美元。雅培的股本回報率為 20.74%，淨利潤率為 31.95%。該業務的季度收入為 109.7 億美元，而分析師預期為 110.3 億美元。在去年同期，該業務的每股收益為 1.19 美元。雅培的季度收入同比增長 7.2%。分析師預計雅培在當前年度的每股收益將達到 5.14 美元。</p>
<h2>雅培增加股息</h2>
<ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
<p>該公司最近宣佈了一項季度股息，已於 2 月 14 日支付。1 月 15 日的股東獲得了 0.59 美元的股息。這相當於年化股息 2.36 美元，收益率為 1.78%。這比雅培之前的季度股息 0.55 美元有所增加。除息日期為 1 月 15 日。雅培的股息支付比率為 30.85%。</p>
<h2>雅培的內部買賣</h2>
<p>在其他雅培的新聞中，執行副總裁 Daniel Gesua Sive Salvadori 於 1 月 30 日以 128.50 美元的平均價格出售了 23771 股公司的股票，總價值為 3054573.50 美元。交易後，該執行副總裁現在持有 125697 股公司股票，價值約為 16152064.50 美元。此次交易使其持股減少了 15.90%。該交易已在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。公司內部人士持有公司股票的 1.10%。</p>
<h2>對雅培的對沖基金觀點</h2>
<p>一些機構投資者和對沖基金最近買賣了 ABT 的股票。Allspring Global Investments Holdings LLC 在第三季度將其在雅培的股份增加了 17.9%。Allspring Global Investments Holdings LLC 目前持有 268538 股雅培的股票，價值 30616000 美元，此前在該期間內又收購了 40783 股。Trilogy Capital Inc.在第三季度將其在雅培的持股增加了 5.6%。Trilogy Capital Inc.目前持有 2503 股雅培的股票，價值 285000 美元，此前在上個季度又購買了 132 股。Copeland Capital Management LLC 在第三季度以約 142000 美元的價格購買了雅培的新股份。My Legacy Advisors LLC 在第三季度將其在雅培的持股增加了 2.3%。My Legacy Advisors LLC 目前持有 4180 股雅培的股票，價值 477000 美元，此前在上個季度又購買了 92 股。最後，Symphony Financial Ltd. Co.在第三季度將其在雅培的持股增加了 11.2%。Symphony Financial Ltd. Co.目前持有 8571 股雅培的股票，價值 964000 美元，此前在上個季度又購買了 863 股。機構投資者和對沖基金持有公司 75.18% 的股票。</p>
<h2>關於雅培</h2>
<p>（獲取免費報告）</p>
<p>雅培（Abbott Laboratories）及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個業務部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培（Abbott Laboratories）</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>沃爾瑪面臨關税壓力，消費者趨勢依然積極</li>
<li>超買股票解析：你應該交易它們嗎？</li>
<li>特斯拉：買入的兩個理由，賣出的一個理由</li>
<li>納斯達克是什麼？完整概述及歷史</li>
<li>你應該長期持有 NVIDIA 股票還是交易它？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培（Abbott Laboratories）嗎？</h2>
<p>在你考慮雅培（Abbott Laboratories）之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而雅培（Abbott Laboratories）並不在名單上。</p>
<p>雖然雅培（Abbott Laboratories）目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>雅培（Abbott Laboratories，NYSE:ABT）股票達到 52 周新高 132.92 美元，交易量為 547,305 股。分析師對該股票的平均評級為 “適度買入”，目標價為 133.06 美元。公司報告上個季度每股收益為 1.34 美元，符合預期，並宣佈季度股息增加至 0.59 美元。內部交易活動包括執行副總裁 Daniel Gesua Sive Salvadori 出售 23,771 股。機構投資者最近也增加了對公司的持股</p>

<p>Abbott Laboratories (NYSE:ABT - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as $132.85 and last traded at $132.92, with a volume of 547305 shares. The stock had previously closed at $132.13.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）股票在週四創下 52 周新高。該公司交易價格最高達到 132.85 美元，最後交易價格為 132.92 美元，成交量為 547305 股。該股票此前收盤價為 132.13 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培將在 2025 年超越醫療保健股票</li>
</ul>
</div><p>ABT has been the topic of a number of analyst reports. Barclays reissued an &#34;overweight&#34; rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Wells Fargo &amp; Company raised their price objective on Abbott Laboratories from $133.00 to $136.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, January 23rd. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, February 12th. Evercore ISI raised their price objective on Abbott Laboratories to $136.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, January 2nd. Finally, Stifel Nicolaus lifted their price target on Abbott Laboratories from $130.00 to $135.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $133.06.</p>
<div class="lb-trans"><p>ABT 一直是多份分析師報告的主題。巴克萊在 1 月 27 日的研究報告中重申了 “增持” 評級，並將雅培的目標價從 149.00 美元上調至 158.00 美元。富國銀行在 1 月 23 日的研究報告中將雅培的目標價從 133.00 美元上調至 136.00 美元，並給予該股票 “增持” 評級。StockNews.com 在 2 月 12 日的研究報告中將雅培的評級從 “強力買入” 下調至 “買入”。Evercore ISI 在 1 月 2 日的研究報告中將雅培的目標價上調至 136.00 美元，並給予該股票 “買入” 評級。最後，斯蒂費爾·尼古拉斯在 1 月 23 日的報告中將雅培的目標價從 130.00 美元上調至 135.00 美元，並給予公司 “買入” 評級。四位股票研究分析師對該股票給予持有評級，十四位給予買入評級，一位給予強力買入評級。根據 MarketBeat.com 的數據，雅培目前的平均評級為 “適度買入”，平均目標價為 133.06 美元。</p>
</div><p><strong>Read Our Latest Report on ABT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ABT 的最新報告</strong></p>
</div><h2>Abbott Laboratories Trading Up 0.4 %</h2>
<div class="lb-trans"><h2>雅培股票上漲 0.4%</h2>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>這些是適合長期投資的頂級健康股票</li>
</ul>
</div><p>The firm has a market capitalization of $230.19 billion, a P/E ratio of 17.35, a PEG ratio of 2.43 and a beta of 0.75. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $119.93 and a 200-day moving average price of $116.53.</p>
<div class="lb-trans"><p>該公司的市值為 2301.9 億美元，市盈率為 17.35，PEG 比率為 2.43，貝塔值為 0.75。該公司的速動比率為 1.14，流動比率為 1.60，債務股本比率為 0.32。該業務的 50 日移動平均價格為 119.93 美元，200 日移動平均價格為 116.53 美元。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion for the quarter, compared to analysts' expectations of $11.03 billion. During the same period in the previous year, the business posted $1.19 earnings per share. Abbott Laboratories's quarterly revenue was up 7.2% on a year-over-year basis. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 1 月 22 日發佈了季度財報。這家醫療產品製造商報告該季度每股收益（EPS）為 1.34 美元，符合分析師的共識預期 1.34 美元。雅培的股本回報率為 20.74%，淨利潤率為 31.95%。該業務的季度收入為 109.7 億美元，而分析師預期為 110.3 億美元。在去年同期，該業務的每股收益為 1.19 美元。雅培的季度收入同比增長 7.2%。分析師預計雅培在當前年度的每股收益將達到 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
</div><p>The business also recently declared a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th were given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.78%. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date was Wednesday, January 15th. Abbott Laboratories's dividend payout ratio is 30.85%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項季度股息，已於 2 月 14 日支付。1 月 15 日的股東獲得了 0.59 美元的股息。這相當於年化股息 2.36 美元，收益率為 1.78%。這比雅培之前的季度股息 0.55 美元有所增加。除息日期為 1 月 15 日。雅培的股息支付比率為 30.85%。</p>
</div><h2>Insider Buying and Selling at Abbott Laboratories</h2>
<div class="lb-trans"><h2>雅培的內部買賣</h2>
</div><p>In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他雅培的新聞中，執行副總裁 Daniel Gesua Sive Salvadori 於 1 月 30 日以 128.50 美元的平均價格出售了 23771 股公司的股票，總價值為 3054573.50 美元。交易後，該執行副總裁現在持有 125697 股公司股票，價值約為 16152064.50 美元。此次交易使其持股減少了 15.90%。該交易已在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。公司內部人士持有公司股票的 1.10%。</p>
</div><h2>Hedge Funds Weigh In On Abbott Laboratories</h2>
<div class="lb-trans"><h2>對雅培的對沖基金觀點</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of ABT. Allspring Global Investments Holdings LLC lifted its stake in shares of Abbott Laboratories by 17.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 268,538 shares of the healthcare product maker's stock valued at $30,616,000 after acquiring an additional 40,783 shares during the period. Trilogy Capital Inc. increased its holdings in Abbott Laboratories by 5.6% in the third quarter. Trilogy Capital Inc. now owns 2,503 shares of the healthcare product maker's stock valued at $285,000 after purchasing an additional 132 shares during the last quarter. Copeland Capital Management LLC bought a new stake in Abbott Laboratories in the third quarter valued at about $142,000. My Legacy Advisors LLC increased its holdings in Abbott Laboratories by 2.3% in the third quarter. My Legacy Advisors LLC now owns 4,180 shares of the healthcare product maker's stock valued at $477,000 after purchasing an additional 92 shares during the last quarter. Finally, Symphony Financial Ltd. Co. increased its holdings in Abbott Laboratories by 11.2% in the third quarter. Symphony Financial Ltd. Co. now owns 8,571 shares of the healthcare product maker's stock valued at $964,000 after purchasing an additional 863 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買賣了 ABT 的股票。Allspring Global Investments Holdings LLC 在第三季度將其在雅培的股份增加了 17.9%。Allspring Global Investments Holdings LLC 目前持有 268538 股雅培的股票，價值 30616000 美元，此前在該期間內又收購了 40783 股。Trilogy Capital Inc.在第三季度將其在雅培的持股增加了 5.6%。Trilogy Capital Inc.目前持有 2503 股雅培的股票，價值 285000 美元，此前在上個季度又購買了 132 股。Copeland Capital Management LLC 在第三季度以約 142000 美元的價格購買了雅培的新股份。My Legacy Advisors LLC 在第三季度將其在雅培的持股增加了 2.3%。My Legacy Advisors LLC 目前持有 4180 股雅培的股票，價值 477000 美元，此前在上個季度又購買了 92 股。最後，Symphony Financial Ltd. Co.在第三季度將其在雅培的持股增加了 11.2%。Symphony Financial Ltd. Co.目前持有 8571 股雅培的股票，價值 964000 美元，此前在上個季度又購買了 863 股。機構投資者和對沖基金持有公司 75.18% 的股票。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>關於雅培</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories）及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個業務部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive</li>
<li>Overbought Stocks Explained: Should You Trade Them?</li>
<li>Tesla: 2 Reasons to Buy, 1 Reason to Run</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>Should You Hold NVIDIA Stock for the Long Haul or Trade It?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培（Abbott Laboratories）</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>沃爾瑪面臨關税壓力，消費者趨勢依然積極</li>
<li>超買股票解析：你應該交易它們嗎？</li>
<li>特斯拉：買入的兩個理由，賣出的一個理由</li>
<li>納斯達克是什麼？完整概述及歷史</li>
<li>你應該長期持有 NVIDIA 股票還是交易它？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培（Abbott Laboratories）嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮雅培（Abbott Laboratories）之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而雅培（Abbott Laboratories）並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培（Abbott Laboratories）目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

雅培實驗室（紐約證券交易所代碼：ABT）創下 52 周新高 - 原因如下